PROF. DR. HO GWO FUANG
Dean Office
Faculty of Medicine
gwohoum.edu.myView CV | |
Personal Homepage | |
Publons | |
Scopus Link | |
Biography | |
Dr Ho Gwo Fuang is a professor and clinical oncologist at Universiti Malaya Medical Centre and Universiti Malaya Specialist Centre, Kuala Lumpur, Malaysia. He was trained at Barts and The London National Health Service (NHS) Trust and The Royal Marsden NHS Trust in London. He attained his Certificate for Completion of Specialist Training (CCST) in 2007 and joined the Faculty of Medicine at Universiti Malaya. He received the Joint Commission International (JCI) Outstanding Young Malaysian Award in 2009 for medical innovation. His research interests involve breast, gastrointestinal, and hepatobiliary cancers. He co-authored the Pan-Asian Adapted ESMO Clinical Practice Guidelines for hepatocellular carcinoma (2020) and ASCO Resource Stratified Guideline for Early Detection for Colorectal Cancer (2019) and Treatment of Patients with Early Stage Colorectal Cancer Resource Stratified Guideline (2019). He is involved in many national and international collaborative research work, as well as the training of new oncologists in Malaysia. |
Publication
Finance
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial
Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study
Candida species and oral mycobiota of patients clinically diagnosed with oral thrush
Sexual Wellbeing and Supportive Care Needs After Cancer in a Multiethnic Asian Setting: A Qualitative Study
Cancer and You
Written for Cancer Patient
Association of plasma Epstein-Barr virus DNA and clinical response in patients with recurrent and/or metastatic nasopharyngeal cancer treated with pembrolizumab or standard-of-care chemotherapy in KEYNOTE-122.
Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial.
A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic HER2-negative breast cancer patients: Evaluation of impact of germline variants in APOBEC3B (AUROR)
Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study